aromatase inhibitor

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Adverse effects

Radiology

More general terms

More specific terms

References

  1. Jump up to: 1.0 1.1 1.2 1.3 1.4 1.5 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 19. American College of Physicians, Philadelphia 2012, 2015, 2019
  2. Jump up to: 2.0 2.1 2.2 Prescriber's Letter 13(5): 2006 Aromatase inhibitors and vaginal estrogen Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220516&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. Becker T, Lipscombe L, Narod S, et al. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012 Sep;60(9):1761-1767. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22985145
  4. Jump up to: 4.0 4.1 Coleman R, de Boer R, Eidtmann H et al Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013 Feb;24(2):398-405. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23047045
    Llombart A, Frassoldati A, Paija O, Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012 Feb;12(1):40-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22014381
  5. Jump up to: 5.0 5.1 Prescriber's Letter 12(9): 2005 Aromatase inhibitors & the Risk of Arthralgias Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=211019&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. Deprecated Reference
  7. Jump up to: 7.0 7.1 Mao JJ et al Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor- related arthralgia: A randomized trial. Cancer. Online July 30, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25077452 <Internet> http://onlinelibrary.wiley.com/doi/10.1002/cncr.28917/abstract
  8. Jump up to: 8.0 8.1 8.2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211827 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961074-1/abstract
    Mayer EL, Burstein HJ Postmenopausal breast cancer: a best endocrine strategy? Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211823 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961206-5/abstract
  9. Henry NL, Azzouz F, Desta Z et al Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012 Mar 20;30(9):936-42 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22331951
  10. Jump up to: 10.0 10.1 10.2 10.3 Hadji P, Aaprob MS, Body JJ et al Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2017 Mar 23;7:1-12. eCollection 2017 Jun. Review <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28413771 Free PMC Article <Internet> http://www.sciencedirect.com/science/article/pii/S2212137417300258
    International Osteoporosis Foundation Public Release: 25-Apr-2017 New guidance for management of aromatase-inhibitor related bone loss in breast cancer. https://www.eurekalert.org/pub_releases/2017-04/iof-ngf042517.php
  11. Jump up to: 11.0 11.1 11.2 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
    Tenti S, Correale P, Cheleschi S, et al. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21(16):5625 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32781535 PMCID: PMC7460580 Free PMC article https://www.mdpi.com/1422-0067/21/16/5625
  12. Jump up to: 12.0 12.1 Hershman DL, Unger JM, Greenlee H et al Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain. A Randomized Clinical Trial. JAMA Netw Open. 2022;5(11):e2241720 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798317
  13. Jump up to: 13.0 13.1 Tan WW, Marienberg ES Fast Five Quiz: Precision Medicine in Cancer Medscape. January 06, 2023 https://reference.medscape.com/viewarticle/954083